Table 1 Patient characteristics
|  | n = 35 |
|---|---|
Gender (male) | 23 (65.7%) |
Age | 69 (30–86) |
BMI | 20.9 (15.5–30.9) |
White blood cell (μl) | 6340 (3140–12,960) |
Neutrophil (μl) | 4150 (1380–10,640) |
Lymphocyte (μl) | 1310 (690–3220) |
NLR | 2.3 (0.8–7.6) |
Hemoglobin (g/dl) | 12.2 (7.3–15.7) |
Platelet count (× 104/μl) | 29.6 (13.1–61.4) |
CRP (mg/dl) | 0.1 (0.1–13.5) |
Total protein (g/dl) | 6.7 (4.5–8.2) |
Albumin (g/dl) | 3.8 (2.1–4.4) |
Cholinesterase (U/l) | 240 (107–410) |
CEA (ng/ml) | 2.4 (0.5–1380) |
CA19-9 (U/ml) | 19.8 (0.5–159.5) |
CA125 (U/ml) | 11.5 (4.0–247.3) |
Tumor differentiation (poorly or signet) | 10 (28.6) |
Tumor type (3, 4) | 31 (88.6%) |
Tumor location (UML) | 18 (51.4%) |
T 4a | 28 (80.0%) |
N > 2a | 18 (51.4%) |
clinical Stage II/III/IVa | 7 (20.0%)/16 (45.7%)/12 (34.3%) |